[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Clinical Notes
March 21, 1964

Dangerous Potentiation of Meperidine Hydrochloride by Pargyline Hydrochloride

Author Affiliations

Los Angeles

From the Research Foundation for Circulatory Disease, Beverly Hills, Calif. Dr. Vigran is attending physician at Cedars of Lebanon Hospital.

JAMA. 1964;187(12):953-954. doi:10.1001/jama.1964.03060250071021
Abstract

INTEREST IN the role of monoamine oxidase (MAO) inhibitors in the treatment of hypertensive disease has been stimulated by the widely noted observation that therapy with potent monoamine oxidase inhibitors produces marked orthostatic hypotension. Originally a troublesome side reaction, this property has since been utilized in the treatment of hypertension. Recently, the introduction of a new drug, pargyline hydrochloride (Eutonyl), with powerful MAO inhibiting properties and antihypertensive effects, has been used as a therapeutic agent in the treatment of hypertension.

Little known is the fact that the effects of meperidine (Demerol) hydrochloride are markedly potentiated when administered to patients concurrently taking MAO inhibitors. To my knowledge, this has not been reported in the American literature with the exception of a precaution concerning the drug,1 although it has been discussed by the British.2-6 It is felt that a timely warning of the danger of meperidine administration to patients being

First Page Preview View Large
First page PDF preview
First page PDF preview
×